Artal Group’s Standard BioTools LAB Stock Holding History

Artal Group’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	–	Sell	-168,706	Closed	-$3.7M	–	90
2013 Q3	$3.7M	Sell	168,706 -144,193	-46%	-$2.83M	0.12%	64
2013 Q2	$5.46M	Buy	+312,899	New	+$5.49M	0.17%	62

Other funds holding LAB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

NCGI

Next Century Growth Investors Plymouth, Minnesota $1.38B AUM 102.34% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group's LAB Position: Q4 2013 in Review

Artal Group sold out of Standard BioTools (LAB) in Q4 2013, closing a stake of 168,706 shares — an estimated $3.7M sold.

Artal Group first reported a position in LAB in Q2 2013 and held it in 2 quarters. The position peaked at $5.46M in Q2 2013. 100 funds tracked by Wall St. Rank hold LAB as of Q4 2013.

Artal Group reported no remaining Standard BioTools position as of Q4 2013 after selling out during the quarter.
Artal Group sold 168,706 Standard BioTools shares in Q4 2013, an estimated $3.7M.
Artal Group first reported a position in Standard BioTools in Q2 2013 and held it in 2 quarters.
Artal Group's Standard BioTools position peaked at $5.46M in Q2 2013.
100 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2013.

Based on Artal Group's 13F filing for Q4 2013, filed 14 Feb 2014.